• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Complexity of SIRT2 in Chronic Liver Disease: Liver SIRT2 Promotes Hepatocellular Carcinoma Development.

作者信息

Li Xinjian, Lu Shaolei, Huang Chiung-Kuei

机构信息

Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, Louisiana.

Department of Pathology and Laboratory Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island.

出版信息

Cell Mol Gastroenterol Hepatol. 2025;19(7):101512. doi: 10.1016/j.jcmgh.2025.101512. Epub 2025 Apr 22.

DOI:10.1016/j.jcmgh.2025.101512
PMID:40280175
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12198020/
Abstract
摘要

相似文献

1
The Complexity of SIRT2 in Chronic Liver Disease: Liver SIRT2 Promotes Hepatocellular Carcinoma Development.SIRT2在慢性肝病中的复杂性：肝脏SIRT2促进肝细胞癌发展。
Cell Mol Gastroenterol Hepatol. 2025;19(7):101512. doi: 10.1016/j.jcmgh.2025.101512. Epub 2025 Apr 22.
2
Suppression of Hepatocellular Carcinoma by Deletion of SIRT2 in Hepatocytes via Elevated C/EBPβ/GADD45γ.通过升高C/EBPβ/GADD45γ，肝细胞中SIRT2缺失抑制肝细胞癌
Cell Mol Gastroenterol Hepatol. 2025;19(7):101494. doi: 10.1016/j.jcmgh.2025.101494. Epub 2025 Mar 11.
3
P5CS deacetylation mediated by SIRT2 facilitates tumor growth by enhancing mitochondrial respiration in hepatocellular carcinoma.由SIRT2介导的P5CS去乙酰化通过增强肝癌细胞中的线粒体呼吸来促进肿瘤生长。
Oncogene. 2025 May 27. doi: 10.1038/s41388-025-03456-3.
4
Oridonin Ameliorates Metabolic-Dysfunction-Associated Fatty Liver Disease by Inhibiting PANoptosis via Modulating SIRT2/NLRP3 Pathway.冬凌草甲素通过调节SIRT2/NLRP3通路抑制PAN凋亡来改善代谢功能障碍相关脂肪性肝病。
Phytother Res. 2025 Aug 6. doi: 10.1002/ptr.70055.
5
Deacetylase SIRT2 Inhibition Promotes Microglial M2 Polarization Through Axl/PI3K/AKT to Alleviate White Matter Injury After Subarachnoid Hemorrhage.去乙酰化酶SIRT2抑制通过Axl/PI3K/AKT促进小胶质细胞M2极化以减轻蛛网膜下腔出血后的白质损伤。
Transl Stroke Res. 2024 Aug 5. doi: 10.1007/s12975-024-01282-5.
6
Sirt2 deficiency aggravates intramuscular adipose tissue infiltration and impairs myogenesis with aging in male mice.Sirt2基因缺失会加剧雄性小鼠肌肉内脂肪组织浸润，并随着衰老损害其肌肉生成。
Biogerontology. 2025 Apr 21;26(3):93. doi: 10.1007/s10522-025-10238-7.
7
SIRT2 Regulates the SMARCB1 Loss-Driven Differentiation Block in ATRT.SIRT2调节ATRT中由SMARCB1缺失驱动的分化阻滞。
Mol Cancer Res. 2025 Jun 3;23(6):515-529. doi: 10.1158/1541-7786.MCR-24-0926.
8
Fn14 Controls the SIRT2-Mediated Deacetylation of Slug to Inhibit the Metastasis of Epithelial Ovarian Cancer.Fn14通过控制SIRT2介导的Slug去乙酰化来抑制上皮性卵巢癌转移。
Adv Sci (Weinh). 2025 Jul;12(27):e2501552. doi: 10.1002/advs.202501552. Epub 2025 May 8.
9
Virtual Screening Combined with Enzymatic Assays to Guide the Discovery of Novel SIRT2 Inhibitors.虚拟筛选结合酶活性测定指导新型 SIRT2 抑制剂的发现。
Int J Mol Sci. 2023 May 27;24(11):9363. doi: 10.3390/ijms24119363.
10
Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.计算机断层扫描在慢性肝病成人肝细胞癌诊断中的应用。
Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD013362. doi: 10.1002/14651858.CD013362.pub2.

本文引用的文献

1
Suppression of Hepatocellular Carcinoma by Deletion of SIRT2 in Hepatocytes via Elevated C/EBPβ/GADD45γ.通过升高C/EBPβ/GADD45γ，肝细胞中SIRT2缺失抑制肝细胞癌
Cell Mol Gastroenterol Hepatol. 2025;19(7):101494. doi: 10.1016/j.jcmgh.2025.101494. Epub 2025 Mar 11.
2
Management of Hepatocellular Carcinoma: A Review.肝细胞癌的管理：综述
JAMA Surg. 2023 Apr 1;158(4):410-420. doi: 10.1001/jamasurg.2022.7989.
3
Hepatocellular carcinoma.肝细胞癌
Lancet. 2022 Oct 15;400(10360):1345-1362. doi: 10.1016/S0140-6736(22)01200-4. Epub 2022 Sep 6.
4
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.IMbrave150研究的更新疗效和安全性数据：阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌。
J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.
5
SIRT2-mediated deacetylation and deubiquitination of C/EBPβ prevents ethanol-induced liver injury.SIRT2介导的C/EBPβ去乙酰化和去泛素化可预防乙醇诱导的肝损伤。
Cell Discov. 2021 Oct 12;7(1):93. doi: 10.1038/s41421-021-00326-6.
6
Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4α.Sirtuin 2 通过去乙酰化肝细胞核因子 4α 预防肝脂肪变性和代谢紊乱。
Hepatology. 2021 Aug;74(2):723-740. doi: 10.1002/hep.31773. Epub 2021 May 24.
7
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
8
Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells.Sirt2 抑制增强了肿瘤反应性 T 细胞的代谢适应性和效应功能。
Cell Metab. 2020 Sep 1;32(3):420-436.e12. doi: 10.1016/j.cmet.2020.07.008. Epub 2020 Aug 7.
9
Ten-Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild-Type Isocitrate Dehydrogenase 1.Ten-Eleven 易位 1 促进野生型异柠檬酸脱氢酶 1 的胆管癌恶性进展。
Hepatology. 2021 May;73(5):1747-1763. doi: 10.1002/hep.31486.
10
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.